Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. Export

@article{citeulike:977063, abstract = {Two different severe acute respiratory syndrome (SARS) vaccine strategies were evaluated for their ability to protect against live SARS coronavirus (CoV) challenge in a murine model of infection. A whole killed (inactivated by beta-propiolactone) SARS-CoV vaccine and a combination of two adenovirus-based vectors, one expressing the nucleocapsid (N) and the other expressing the spike (S) protein (collectively designated Ad S/N), were evaluated for the induction of serum neutralizing antibodies and cellular immune responses and their ability to protect against pulmonary SARS-CoV replication. The whole killed virus (WKV) vaccine given subcutaneously to 129S6/SvEv mice was more effective than the Ad S/N vaccine administered either intranasally or intramuscularly in inhibiting SARS-CoV replication in the murine respiratory tract. This protective ability of the WKV vaccine correlated with the induction of high serum neutralizing-antibody titres, but not with cellular immune responses as measured by gamma interferon secretion by mouse splenocytes. Titres of serum neutralizing antibodies induced by the Ad S/N vaccine administered intranasally or intramuscularly were significantly lower than those induced by the WKV vaccine. However, Ad S/N administered intranasally, but not intramuscularly, significantly limited SARS-CoV replication in the lungs. Among the vaccine groups, SARS-CoV-specific IgA was found only in the sera of mice immunized intranasally with Ad S/N, suggesting that mucosal immunity may play a role in protection for the intranasal Ad S/N delivery system. Finally, the sera of vaccinated mice contained antibodies to S, further suggesting a role for this protein in conferring protective immunity against SARS-CoV infection.}, address = {University of British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4, Canada.}, author = {See, R. H. and Zakhartchouk, A. N. and Petric, M. and Lawrence, D. J. and Mok, C. P. and Hogan, R. J. and Rowe, T. and Zitzow, L. A. and Karunakaran, K. P. and Hitt, M. M. and Graham, F. L. and Prevec, L. and Mahony, J. B. and Sharon, C. and Auperin, T. C. and Rini, J. M. and Tingle, A. J. and Scheifele, D. W. and Skowronski, D. M. and Patrick, D. M. and Voss, T. G. and Babiuk, L. A. and Gauldie, J. and Roper, R. L. and Brunham, R. C. and Finlay, B. B.}, citeulike-article-id = {977063}, citeulike-linkout-0 = {http://dx.doi.org/10.1099/vir.0.81579-0}, citeulike-linkout-1 = {http://view.ncbi.nlm.nih.gov/pubmed/16476986}, citeulike-linkout-2 = {http://www.hubmed.org/display.cgi?uids=16476986}, doi = {10.1099/vir.0.81579-0}, issn = {0022-1317}, journal = {J Gen Virol}, keywords = {ecu, immunology}, month = {March}, number = {Pt 3}, pages = {641--650}, posted-at = {2006-12-06 20:12:29}, priority = {2}, title = {Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.}, url = {http://dx.doi.org/10.1099/vir.0.81579-0}, volume = {87}, year = {2006} }

TY - JOUR ID - citeulike:977063 L3 - citeulike-article-id:977063 N2 - Two different severe acute respiratory syndrome (SARS) vaccine strategies were evaluated for their ability to protect against live SARS coronavirus (CoV) challenge in a murine model of infection. A whole killed (inactivated by beta-propiolactone) SARS-CoV vaccine and a combination of two adenovirus-based vectors, one expressing the nucleocapsid (N) and the other expressing the spike (S) protein (collectively designated Ad S/N), were evaluated for the induction of serum neutralizing antibodies and cellular immune responses and their ability to protect against pulmonary SARS-CoV replication. The whole killed virus (WKV) vaccine given subcutaneously to 129S6/SvEv mice was more effective than the Ad S/N vaccine administered either intranasally or intramuscularly in inhibiting SARS-CoV replication in the murine respiratory tract. This protective ability of the WKV vaccine correlated with the induction of high serum neutralizing-antibody titres, but not with cellular immune responses as measured by gamma interferon secretion by mouse splenocytes. Titres of serum neutralizing antibodies induced by the Ad S/N vaccine administered intranasally or intramuscularly were significantly lower than those induced by the WKV vaccine. However, Ad S/N administered intranasally, but not intramuscularly, significantly limited SARS-CoV replication in the lungs. Among the vaccine groups, SARS-CoV-specific IgA was found only in the sera of mice immunized intranasally with Ad S/N, suggesting that mucosal immunity may play a role in protection for the intranasal Ad S/N delivery system. Finally, the sera of vaccinated mice contained antibodies to S, further suggesting a role for this protein in conferring protective immunity against SARS-CoV infection. IS - Pt 3 JF - J Gen Virol SN - 0022-1317 AD - University of British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4, Canada. EP - 650 TI - Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. VL - 87 SP - 641 KW - ecu KW - immunology AU - See, RH AU - Zakhartchouk, AN AU - Petric, M AU - Lawrence, DJ AU - Mok, CP AU - Hogan, RJ AU - Rowe, T AU - Zitzow, LA AU - Karunakaran, KP AU - Hitt, MM AU - Graham, FL AU - Prevec, L AU - Mahony, JB AU - Sharon, C AU - Auperin, TC AU - Rini, JM AU - Tingle, AJ AU - Scheifele, DW AU - Skowronski, DM AU - Patrick, DM AU - Voss, TG AU - Babiuk, LA AU - Gauldie, J AU - Roper, RL AU - Brunham, RC AU - Finlay, BB PY - 2006/03// UR - http://dx.doi.org/10.1099/vir.0.81579-0 ER -